Inclisiran (Leqvio)
What clinical trials found
siRNA (blocks PCSK9 production in the liver)
Injectable, only twice a year after the first two starter doses. Approved 2021. ORION trials showed sustained LDL reduction with infrequent dosing versus the every-2-4-week PCSK9 antibodies.
ORION-10 / ORION-11Inclisiran (Leqvio)
1 community report
Outcome
- Well tolerated & effective100% (n=1)
- Based on 1 report
Would recommend
- Yes100% (n=1)
- Based on 1 report
Coverage outcome
- Approved after appeal100% (n=1)
- Based on 1 report
Price paid per month
$150 – $150, median $150 (n=1)